Focus on real-time company dynamics and release fresh news from Constream Biotech
Academic Information
2025.03.27
Seizing the Opportunity: SOX17, the Next PD-1?
The immune system is the body's core defense against tumors, but cancer cells often camouflage themselves through "immune escape" mechanisms to avoid detection and attack by immune cells. Currently, immune checkpoint therapy, represented by PD-1/PD-L1 inhibitors, has achieved breakthroughs in advanced cancers, but its effectiveness is limited in early-stage tumors (such as colorectal cancer).
2025.01.09
Xi News | Synthetic Fab HuCAL GOLD library screening helps Fizeto monoclonal antibody to market
On January 8, 2025, Tianjing Bio's application for the marketing of its CD38 antibody injection, Fizetomab, was accepted by the NMPA. This milestone is undoubtedly a new ray of hope for the second-line treatment of multiple myeloma patients.
2025.01.05
The commercial development of antibody therapeutics is a global endeavor involving tens of thousands of biopharmaceutical companies and supporting service organizations. Their combined efforts have resulted in over 200 antibody therapeutics on the market to date, with nearly 1400 more product candidates in various stages of clinical trials for a wide range of diseases.
2025.01.02
STEAP1 belongs to the prostate transmembrane epithelial antigen (STEAP) family, which, besides STEAP1, includes STEAP2, STEAP3, and STEAP4. These proteins are involved in numerous biological processes, including apoptosis and proliferation, oxidative stress, and intracellular and extracellular molecular transport.
27
2025
/
03
05
2025
/
01
02
2025
/
01
Subscription Information
We will send you real-time information regularly!
Shanghai Constream biotechnology Co., Ltd.
Tel: 021-59255902
Address: 3rd Floor, Building 28, No. 10688, Beiqing Highway, Qingpu District, Shanghai
Mobile Website
Official Account
Copyright © 2024 Shanghai Constream biotechnology Co., Ltd